Difficulties in efficiently propagating

No abstract

The oncoproteins of the DNA tumor viruses, adenovirus E1A, simian virus 40 T antigen, and papillomavirus E7, each interact with the retinoblastoma family of tumor suppressors, leading to cell cycle stimulation, apoptosis induction, and cellular transformation. These proteins utilize a conserved LXCXE motif, which is also found in cellular proteins, to target the retinoblastoma family. Here, we describe a herpesvirus protein that shares a subset of the properties of the DNA tumor virus oncoproteins but maintains important differences as well. The human cytomegalovirus pp71 protein employs an LXCXD motif to attack the retinoblastoma family members and induce DNA synthesis in quiescent cells. pp71 binds to and induces the degradation of the hypophosphorylated forms of the retinoblastoma protein and its family members p107 and p130 in a proteasome-dependent manner. However, pp71 does not induce apoptosis and fails to transform cells. Thus, the similarities and differences in comparison to E1A, T antigen, and E7 make pp71 an interesting new tool with which to further dissect the role of the retinoblastoma/E2F pathway in cellular growth control and carcinogenesis.Viruses are reliant upon their host cells for their replication, and thus, they have evolved methods to efficiently alter the cellular processes that are essential to their duplication and dissemination. Since the repertoire of proteins expressed by viruses is constrained by their relatively small genomes, they generally target important cellular processes, and the means by which they attack them must be effective. Thus, the analysis of how individual viral proteins commandeer and disrupt cellular proteins and networks has been a powerful approach for investigating fundamental mechanisms in cell biology. For example, adenovirus E1A, simian virus 40 (SV40) T antigen, and papillomavirus E7 continue to be invaluable tools in the molecular dissection of the processes governed by the retinoblastoma (Rb) family of tumor suppressors. Here, we demonstrate that a herpesvirus protein, the human cytomegalovirus (HCMV) phosphoprotein 71 (pp71), shares some, but not all, of the properties of these three oncoproteins from the DNA tumor viruses and thus represents a new means by which a viral protein alters cell biology.HCMV is a ubiquitous human pathogen, and a new infection or the reactivation of a latent infection in immunocompromised individuals can result in life-threatening disease. HCMV infection may also play a role in proliferative diseases such as atherosclerosis (27) and restenosis (38). Thus, we and others have been exploring how HCMV alters cell cycle progression (reviewed in reference 23). Infection of cells brought to quiescence either by contact inhibition or serum starvation results in an abortive mitogenic response with an increase in the level of cyclin E protein and kinase activity (4, 18). However, cyclin A is not induced, and cells do not synthesize host genomic DNA (4, 24). Thus, infection of quiescent cells stimulates their reentry into the cell cycl...

Infection of cultured cells with Kaposi's sarcoma associated herpesvirus (KSHV) typically establishes a latent infection, in which only a few viral genes are expressed. Recently, it has been reported that a subset of lytic genes are transiently expressed very early after viral entry but that this burst of abortive lytic gene expression is terminated with the supervention of latency (H. H. Krishnan, P. P. Naranatt, M. S. Smith, L. Zeng, C. Bloomer, and B. Chandran, J. Virol. 78:3601-3620, 2004). To identify molecules imported into cells by KSHV that might influence this gene expression program, we have examined the protein composition of the KSHV particle. Immunoblotting of virus particles demonstrated that RTA, the lytic switch protein, and RAP, a viral protein that is a transcriptional and cell cycle modulator, were both incorporated into virus particles. In a second approach, polypeptides isolated from purified virions were identified by mass-spectrometric analysis of their constituent tryptic peptides. With this approach we were able to identify 18 major virion proteins, including structural, regulatory, and signaling proteins of both viral and cellular origin.

However, the intracellular levels of one virion mRNA, encoding the viral protease, were much lower than those of transcripts not packaged in the virus particle, strongly suggesting that it may be incorporated by a specific mechanism.

The human cytomegalovirus UL47 open reading frame encodes a 110-kDa protein that is a component of the virion tegument. We have constructed a cytomegalovirus mutant, ADsubUL47, in which the central portion of the UL47 open reading frame has been replaced by two marker genes. The mutant replicated to titers 100-fold lower than those for wild-type virus after infection at either a high or a low input multiplicity in primary human fibroblasts but was substantially complemented on cells expressing UL47 protein. A revertant virus in which the mutation was repaired, ADrevUL47, replicated with wild-type kinetics. Mutant virions lacked UL47 protein and contained reduced amounts of UL48 protein. The mutant was found to be less infectious than wild-type virus, and a defect very early in the replication cycle was observed. Transcription of the viral immediate-early 1 gene was delayed by 8 to 10 h. However, this delay was not the result of a defect in virus entry or of the inability of virion proteins to transactivate the major immediate-early promoter. We also show that the UL47 protein coprecipitated with the UL48 and UL69 tegument proteins and the UL86-encoded major capsid protein. We propose that a UL47-containing complex is involved in the release of viral DNA from the disassembling virus particle and that the loss of UL47 protein causes this process to be delayed.

SUMMARYHepatitis C virus (HCV) infects more than 3% of the world's population, leading to an increased risk of cirrhosis and hepatocellular carcinoma. The current standard of care, a combination of pegylated interferon alfa and ribavirin, is poorly tolerated and often ineffective against the most prevalent genotype of the virus, genotype 1. The very recent approval of boceprevir and telaprevir, two HCV protease inhibitors, promises to significantly improve treatment options and outcomes. In addition to the viral protease NS3 and the viral polymerase NS5B, direct-acting antivirals are now in development against NS5A. A multifunctional phosphoprotein, NS5A is essential to HCV genome replication, but has no known enzymatic function. Here we report how the design of small-molecule inhibitors against NS5A has evolved from promising monomers to highly potent dimeric compounds effective against many HCV genotypes. We also highlight recent clinical data and how the inhibitors may bind to NS5A, itself capable of forming dimers. HEPATITIS C VIRUS (HCV): AN INTERNATIONAL HEALTH CONCERNHepatitis C virus (HCV) infects approximately 170 million individuals, with an estimated 2.3-4.7 million new infections each year (1). The primary mode of transmission of HCV is via exposure to infected blood, including transfusions from infected donors, and through injection drug use. It is estimated that 15-30% of all HCV infections will spontaneously clear, but the remaining 70-85% of infections will develop into chronic hepatitis (2, 3). Chronic infections can subsequently lead to steatosis, cirrhosis and hepatocellular carcinoma (4). Among all recognized positive-strand RNA viruses, the ability to establish a chronic infection is exclusive to HCV (5), although how the virus mediates persistence remains unknown.Current treatment options for HCV are relatively poor. The standard of care is often a grueling 48-week combination of pegylated interferon alfa (IFN-α) and the nucleoside analogue ribavirin. Effective clearance of the virus is achieved in less than 50% of genotype

Hepatitis C Virus (HCV) is a leading cause of liver disease and represents a significant public health challenge. Treatments for this disease are inadequate and improved antiviral therapies are necessary. Several such antivirals are in development, most of which target the well-characterized NS3 protease or the NS5B polymerase. In contrast, the nonstructural 4B (NS4B) protein, though essential for HCV RNA replication, has been the subject of few pharmacological studies. One of the functions ascribed to this protein is the ability to form intracellular membrane-associated foci (MAF), which are believed to be related to the sites of viral replication. Here, we report the identification of a small molecule that inhibits HCV replication and disrupts the organization of these MAF. Genetic analysis links the compound’s mode of action to the NS4B gene product, and transient transfections of NS4B-GFP demonstrate that treatment with this compound can lead to the formation of novel elongated assemblies of NS4B. Furthermore, an in vitro dynamic light scattering assay provides evidence that the second amphipathic helix of NS4B may be the target of the drug. Our results demonstrate that this molecule represents a new potential class of HCV inhibitors and also provides us with a useful tool for studying the HCV life cycle.